Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
09 Enero 2024 - 6:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that its Chief Operating Officer, Kristen Oelschlager,
has been named to The Healthcare Technology Report’s Top 25 Women
Leaders in Biotechnology of 2023. The honorees “stand as a driving
force, ensuring diverse perspectives on scientific breakthroughs
and groundbreaking therapies,” according to the publication. “Their
achievements serve as inspiration, paving the way for future
generations of women leaders in biotech to continue shaping the
future of healthcare.”
“I am immensely proud of Kristen for earning this designation,”
said Derek Maetzold, president and chief executive officer of
Castle Biosciences. “As one of our company’s founders, Kristen has
been invaluable to the success of our organization. To be honored
among the nation’s elite women leaders in biotechnology is a
testament to her fortitude and tenacious leadership.”
Oelschlager joined Castle Biosciences in 2008 as the executive
director of operations, being promoted to vice president of
clinical operations in 2013, senior vice president of clinical
operations in 2018 and to her current role of chief operating
officer in 2021. Her extensive background of more than 15 years in
clinical nursing, clinical operations services and clinical
research brought a unique perspective that has been instrumental in
Castle's success and growth from an early start-up to a thriving
public company with almost 600 employees. Additionally, she has
been influential in shaping the Company’s strategy and people-first
culture, which have, in turn, helped garner Castle’s designation as
a national Top Workplace for the last two consecutive years.
Oelschlager is one of the company’s three founders, alongside
President and CEO, Derek Maetzold, and Chief Commercial Officer,
Toby Juvenal.
The comprehensive list of the Top 25 Women Leaders in
Biotechnology of 2023 can be viewed here.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME
and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
About The Healthcare Technology Report
The Healthcare Technology Report provides market research and
insights, business news, investment activity updates and important
corporate developments related to the healthcare technology sector.
Based in New York City, the firm is run by a seasoned team of
editors, writers and media professionals highly knowledgeable on
healthcare technology and the various companies, executives and
investors that make up the sector.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240109418730/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com Media Contact: Allison
Marshall amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024